Alzheimer’s disease remains the leading cause of dementia globally, profoundly affecting millions of individuals and their families. The quest for effective treatments is critical, and recent studies involving glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, have garnered attention for their potential neuroprotective effects. GLP-1 medications, commonly used for type 2 diabetes, have been studied for their role in cognitive function and neurodegenerative diseases. Novo’s EVOKE Alzheimer’s trials investigated whether semaglutide could slow cognitive decline in Alzheimer’s disease patients. Although the trials showed that semaglutide did not significantly slow the progression of Alzheimer’s, they did observe improvements in some brain biomarkers associated with the disease. These biomarkers offer insights into the biological processes at play and may guide future therapeutic strategies. Understanding the complex nature of Alzheimer’s is vital. Its pathology includes amyloid-beta accumulation, tau protein tangles, inflammation, and neurodegeneration. Treatments targeting these pathways have been challenging to develop. The partial positive biomarker responses to semaglutide hint at the drug’s modulatory effects on brain health, possibly through improved insulin signaling or reducing neuroinflammation. The science behind GLP-1 receptor agonists and Alzheimer's is evolving. While semaglutide is not yet a cure or a definitive treatment for dementia, ongoing research into GLP-1 medications may open doors to novel interventions. It emphasizes the importance of clinical trials—regardless of whether they meet their primary endpoints—and how each contributes to the broader knowledge needed to combat Alzheimer's. Patients and caregivers should remain informed about emerging therapies and supportive care options while participating in or following ongoing research studies. The journey toward effective Alzheimer’s treatments is complex, but every scientific advancement, including insights from semaglutide's trials, moves us closer to a future with better management and possibly prevention. This research underscores the dynamic intersection between diabetes medications and neurodegenerative diseases, highlighting an exciting area of medical science where multidisciplinary approaches might yield breakthroughs in dementia care.